Atrium Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.00 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $8.28Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $141.6M Enterprise Value −$240.9M Shares Outstanding 17.1M diluted Next Earnings Date27 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Avidity Biosciences has successfully validated its proprietary Antibody Oligonucleotide Conjugates (AOCs) platform, demonstrating the first-ever targeted delivery of RNA into muscle tissue. This scientific breakthrough culminated in a definitive agreement to be acquired by Novartis AG for $72.00 per share in cash, valuing the company at approximately $12 billion. The transaction closed in late February 2026, with Avidity's early-stage precision cardiology programs successfully spun off into a newly launched public entity, Atrium Therapeutics (retaining the ticker $RNA). Given that the acquisition has been completed, the investment thesis for Avidity as an independent entity has played out, and investors should transition to monitoring Novartis's integration of the muscle franchise or evaluate the newly formed Atrium Therapeutics. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$25.00 Mean target$25.00 High · most bullish analyst$25.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Preclinical or clinical safety setbacks in cardiac delivery of siRNA, leading to clinical holds or program terminations, combined with rapid cash burn of its $270 million balance before achieving proof-of-concept. Base CaseCentral scenario Novartis successfully integrates Avidity's late-stage muscle disease franchise (del-desiran for DM1, del-zota for DMD44, and del-brax for FSHD), leveraging its global commercial infrastructure to maximize the market potential of the AOC platform. Meanwhile, Atrium Therapeutics successfully advances its precision cardiology candidates into clinical trials. Bull CaseUpside scenario Successful clinical translation of the AOC platform to cardiac tissue via ATR 1072 and ATR 1086, unlocking a multi-billion dollar precision cardiology market, supplemented by milestone payments from BMS and Eli Lilly collaborations. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |